Drug interactions
Selpercatinib + Sorafenib
Severity: Moderate
Selpercatinib and Sorafenib: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Both drugs can prolong the QT interval, so combined use may raise the risk of serious ventricular arrhythmia. Selpercatinib labeling advises caution with other QT-prolonging agents.
What this interaction means in plain words
Selpercatinib and Sorafenib can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Selpercatinib belongs to Oncology; Sorafenib belongs to Oncology.
Why it happens
Additive QT prolongation through pharmacodynamic effects.
What to do
Monitor ECG and electrolytes at baseline and periodically. Correct potassium and magnesium before and during therapy.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Selpercatinib and Sorafenib, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Sorafenib
Other interactions of Selpercatinib
Frequently asked questions
Can I take Selpercatinib with Sorafenib?
MediHelp rates the interaction as moderate. Selpercatinib and Sorafenib can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Both drugs can prolong the QT interval, so combined use may raise the risk of serious ventricular arrhythmia. Selpercatinib labeling advises caution with other QT-prolonging agents.
How serious is the interaction between Selpercatinib and Sorafenib?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor ECG and electrolytes at baseline and periodically. Correct potassium and magnesium before and during therapy.
What other medicines interact with Sorafenib?
MediHelp also lists interactions of Sorafenib with, for example, Adagrasib, Amiodarone, Amisulpride. The full list is on the Sorafenib page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
